Citations

Mayo Clinic

Showing 10 of 108572 citations.

New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma
Landgren, Ola , Rajkumar, S. Vincent

Clinical Cancer Research | November 15, 2016 | Volume: 22 | Issue: 22 | Pages: 5428-5433

10.1158/1078-0432.ccr-16-0866 | PMID 28151710 Get It

Abstract Over the past few years, the management of multiple myeloma has changed. We have new guidelines regarding how to set the diagnosis, when to initiate therapy, and how to monitor treatment response. In 2014, the updated International Myeloma Working Group (IMWG) diagnostic criteria changed the definition of multiple myeloma from being a disease defined by symptoms to a disease defined by biomarkers. Today, modern combination therapies have reported up to 60% to 80% of patients reaching a complete response. As a logical and necessary step forward, investigators have explored strategies to detect minimal residual disease (MRD) and its correlation with clinical outcomes. Recent meta-analysis data show that MRD negativity is associated with longer progression-free survival and overall survival. In 2016, the updated IMWG response criteria include MRD as the deepest level of treatment response in multiple myeloma. Simultaneously, we are still quite behind in our understanding of the heterogeneous biology of multiple myeloma and its implications for therapy. Emerging DNA sequencing data show that newly diagnosed multiple myeloma patients have a broad range of mutations, which are distributed unevenly in multiple parallel subclones already present at diagnosis. To move beyond the ill-defined category of “high-risk multiple myeloma,” which confers to approximately 25% of all newly diagnosed patients, prospective studies are needed to dissect tumor biology and define multiple myeloma subtypes, and, based on biology, seek to define rational therapies for individual subtypes. This article discusses novel insights and gives perspectives on diagnosis and MRD monitoring and future directions for prognosis and clinical management of multiple myeloma. Clin Cancer Res; 22(22); 5428–33. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
Survey of Current Practices from the International Stereotactic Body Radiotherapy Consortium (Isbrtc) for Head and Neck Cancers
Karam, Irene , Yao, Min , Heron, Dwight E. , Poon, Ian , Koyfman, Shlomo A. , Yom, Sue S. , Siddiqui, Farzan , Lartigau, Éric, Cengiz, Mustafa , Yamazaki, Hideya , Hara, Wendy, Phan, Jack , Vargo, John A. , Lee, Victor , Foote, Robert L. , Harter, K. William, Lee, Nancy Y. , Sahgal, Arjun , Lo, Simon S. , Yom, Sue S , Phan, Jack

Future Oncology | November 15, 2016 | Volume: 13 | Issue: 7 | Pages: 603-613

10.2217/fon-2016-0403 | PMID 27842456 Get It

Rifampin-Based Combination Therapy Is Active in Foreign-Body Osteomyelitis after Prior Rifampin Monotherapy
Brinkman, Cassandra L., Schmidt-Malan, Suzannah M., Mandrekar, Jayawant N. , Patel, Robin , Patel, Robin

Antimicrobial Agents and Chemotherapy | November 15, 2016 | Volume: 61 | Issue: 2 | Pages: No page available

10.1128/aac.01822-16 | PMID 27855064 Get It

ABSTRACT Staphylococcal prosthetic joint infections (PJIs) are associated with biofilm formation, making them difficult to treat; if managed with debridement and implant retention, rifampin-based therapy is usually employed. Rifampin resistance potentially challenges PJI treatment. In investigating the effects of rifampin monotherapy on methicillin-resistant Staphylococcus aureus (MRSA) foreign-body osteomyelitis in rats, we previously demonstrated that rifampin resistance was selected but that it disappeared 14 days following rifampin monotherapy (1) and that rifampin resistance occurred less frequently following two rounds than following one round of rifampin monotherapy (2). Here, we compared rifampin monotherapy followed by rifampin-vancomycin combination therapy to rifampin-vancomycin combination therapy alone in experimental MRSA foreign-body osteomyelitis. Animals treated with rifampin monotherapy followed by rifampin-vancomycin combination therapy had decreased quantities of bacteria 14 days following treatment completion ( P = 0.034) compared to those in animals treated with combination therapy alone. Additionally, some isolates recovered from animals treated with combination therapy alone, although still susceptible to rifampin, had higher MIC, minimum biofilm-inhibitory concentration (MBIC), and minimum biofilm-bactericidal concentration (MBBC) values than those of the inoculating strain. This suggests that rifampin may remain a feasible treatment option in foreign-body-associated orthopedic infections following the selection of rifampin resistance.
Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis
Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Patel, Robin , Park, Kyung Hwa , Schuetz, Audrey N. , Patel, Robin

Antimicrobial Agents and Chemotherapy | November 15, 2016 | Volume: 61 | Issue: 2 | Pages: No page available

10.1128/aac.01644-16 | PMID 27855069 Get It

ABSTRACT We developed a rat model of methicillin-resistant Staphylococcus epidermidis (MRSE) foreign body-associated osteomyelitis and used it to compare tedizolid alone and in combination with rifampin against rifampin alone, vancomycin plus rifampin, and vancomycin alone. A clinical strain of MRSE was inoculated into the proximal tibia, and a stainless steel wire with a precolonized MRSE biofilm was implanted. Following a 1-week infection period, 92 rats received either no treatment ( n = 17) or 14 days of intraperitoneal tedizolid ( n = 15), tedizolid plus rifampin ( n = 15), rifampin ( n = 15), vancomycin plus rifampin ( n = 15), or vancomycin ( n = 15). Quantitative bone and wire cultures were performed after treatment completion and also 1 week after infection in a separate group of five rats. The median quantity of staphylococci in bone after the 1-week infection period was 4.89 log 10 CFU/g bone (interquartile range, 3.83 to 5.33 log 10 CFU/g bone); staphylococci were recovered from all associated wires. A median quantity of staphylococci of 3.70 log 10 CFU/g bone was detected in bones of untreated control rats after 3 weeks. Quantities of staphylococci in bones of all treatment groups except the group receiving vancomycin alone (2.78 log 10 CFU/g) were significantly lower than those for untreated controls, with no staphylococci being detected in the groups receiving rifampin monotherapy, tedizolid-plus-rifampin combination therapy, and vancomycin-plus-rifampin combination therapy. Quantities of staphylococci on wires from all treatment groups that included rifampin were significantly lower than those for untreated controls. No resistance to rifampin, tedizolid, or vancomycin was detected. Tedizolid combined with rifampin was active in a rat model of MRSE foreign body-associated osteomyelitis.
A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands
Qin, Tai, Barron, Lindsey , Xia, Lu , Villarreal, Maria M., Zwaagstra, John C. , Collins, Cathy, Zwieb, Christian, Kodali, Ravindra, Hinck, Cynthia S. , Reddick, Robert L., O'Connor‐McCourt, Maureen D., Sun, Lu‐Zhe , Huang, Haojie , Yang, Junhua , Kim, Sun Kyung , Shu, Chang , Hinck, Andrew P.

Oncotarget | November 15, 2016 | Volume: 7 | Issue: 52 | Pages: 86087-86102

10.18632/oncotarget.13343 | PMID 27863384 Get It

Perceived risks and reasons to smoke cigarettes during pregnancy among Alaska native women
Bronars, Carrie, Patten, Christi A. , Koller, Kathryn R. , Decker, Paul A. , Hanson, Andrew C. , Wolfe, Abbie W., Hughes, Christine A. , Benowitz, Neal L. , Murphy, Neil J. , Thomas, Timothy K. , Patten, Christi , Koller, Kathryn , Hanson, Andrew, Hughes, Christine, Hatsukami, Dorothy K. , Flanagan, Christie A. , Decker, Paul A.

Ethnicity & Health | November 15, 2016 | Volume: 23 | Issue: 1 | Pages: 33-42

10.1080/13557858.2016.1246425 | PMID 27842438 Get It

Immune Therapies in Multiple Myeloma
Kumar, Shaji , Anderson, Kenneth C.

Clinical Cancer Research | November 15, 2016 | Volume: 22 | Issue: 22 | Pages: 5453-5460

10.1158/1078-0432.ccr-16-0868 | PMID 28151713 Get It

Abstract Treatment paradigms have changed rapidly for multiple myeloma, and immune therapies have taken center stage. Advances in therapies for myeloma have led to a dramatic improvement in the survival of patients with this incurable malignancy. The immune system is significantly impaired in patients with myeloma as a result of the disease leading to suppression of normal plasma cells as well the negative effects on cellular immunity. Given this scenario, immune approaches have not been successful until recently. Monoclonal antibodies directed against CD38 (daratumumab) and SLAMF7 (elotuzumab) are already in the clinic, and several other antibodies directed against different plasma cell antigens are under evaluation. Although immune checkpoint inhibition with PD-1 inhibitors had no clinical efficacy when the inhibitors were used as single agents, it has led to some dramatic results when the inhibitors are combined with immunomodulatory drugs such as lenalidomide and pomalidomide. Vaccination strategies have shown in vivo immune responses but no clear clinical efficacy. Newer approaches to vaccination with multiple antigens, used in combinations with immunomodulatory drugs and in the setting of minimal residual disease, have all increased possibility of this approach succeeding. Ex vivo effector cell expansion also appears to be promising and is in clinical trials. Finally, a chimeric antigen receptor T-cell approach appears to have some promise based on isolated reports of success and remains an area of intense investigation. Immune-based approaches can potentially augment or even supplant some of the current approaches and, given the low toxicity profile, may hold great potential in the early treatment of precursor-stage diseases. Clin Cancer Res; 22(22); 5453–60. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
Response by Herrmann et al to Letter Regarding Article, “Vascular Toxicities of Cancer Therapies: The Old and the New—An Evolving Avenue”
Herrmann, Joerg , Yang, Eric H. , Iliescu, Cezar , Marmagkiolis, Konstantinos , Yang, Eric

Circulation | November 14, 2016 | Volume: 134 | Issue: 20 | Pages: No page available

10.1161/circulationaha.116.024415 | PMID 27881502 Get It

Right brain: The neurologist's blessing
Scharf, Eugene , Scharf, Eugene L

Neurology | November 14, 2016 | Volume: 87 | Issue: 20 | Pages: No page available

10.1212/wnl.0000000000003342 | PMID 27906665 Get It

Are ultrasound renal aspects associated with urinary biochemistry in fetuses with lower urinary tract obstruction?
Nassr, Ahmed A. , Koh, Chester J. , Shamshirsaz, Alireza A. , Espinoza, Jimmy , Sangi‐Haghpeykar, Haleh , Sharhan, Dina, Welty, Stephen E. , Angelo, Joseph , Roth, David R. , Belfort, Michael A. , Braun, Michael , Ruano, Rodrigo , Espinoza, J

Prenatal Diagnosis | November 14, 2016 | Volume: 36 | Issue: 13 | Pages: 1206-1210

10.1002/pd.4958 | PMID 27862070 Get It

AbstractObjectiveTo evaluate the association between ultrasonographic renal parameters and urine biochemistry in fetuses with lower urinary tract obstruction (LUTO).MethodsData were collected prospectively from 31 consecutive fetuses with LUTO that underwent vesicocentesis for fetal urinary biochemistry between April 2013 and September 2015. The following renal ultrasound markers were assessed immediately before the vesicocentesis: renal echogenicity, presence of cortical cysts, presence of findings suggestive of ‘renal dysplasia’ (hyperechogenic cystic kidneys with no cortical‐medullary differentiation) and severe oligohydramnios (amniotic fluid < 5th percentile). The association of these parameters to the fetal urinary concentration of sodium, chloride, calcium, osmolality and beta2‐microglobulin was investigated by logistic regression analysis.ResultsThere was no relationship between any of the ultrasonographic fetal renal characteristics and fetal urinary biochemistry.ConclusionsIn LUTO, the ultrasound appearance of the fetal kidneys and urinary biochemistry are not correlated. It may be better to take both ultrasound and biochemistry into account when evaluating fetuses with fetal LUTO. © 2016 John Wiley & Sons, Ltd.